Propanc Biopharma Inc's Comment on Sales, Marketing and Customers
The company plans to market its products internationally and must obtain approval from foreign regulatory authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Australia's Therapeutics Goods Administration (TGA), prior to initiating clinical trials or marketing. Clinical trials will be conducted globally in compliance with Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), and Good Laboratory Practice (GLP) standards. The company intends to conduct a first-in-human Phase Ib study followed by Phase II studies for PRP in patients with advanced solid tumors. Regulatory meetings will be held with the FDA, EMA, and other relevant foreign agencies. Marketing authorization in the European Union requires a centralized procedure overseen by the EMA, which has been affected by the United Kingdom's departure from the EU. In Australia, the TGA regulates pharmaceutical products under the Therapeutic Goods Act 1989. Commercial success will depend in part on coverage and reimbursement from third-party payors.
Propanc Biopharma Inc’s Comment on Sales, Marketing and Customers
The company plans to market its products internationally and must obtain approval from foreign regulatory authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Australia's Therapeutics Goods Administration (TGA), prior to initiating clinical trials or marketing. Clinical trials will be conducted globally in compliance with Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), and Good Laboratory Practice (GLP) standards. The company intends to conduct a first-in-human Phase Ib study followed by Phase II studies for PRP in patients with advanced solid tumors. Regulatory meetings will be held with the FDA, EMA, and other relevant foreign agencies. Marketing authorization in the European Union requires a centralized procedure overseen by the EMA, which has been affected by the United Kingdom's departure from the EU. In Australia, the TGA regulates pharmaceutical products under the Therapeutic Goods Act 1989. Commercial success will depend in part on coverage and reimbursement from third-party payors.
Sources:
Propanc Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Propanc Biopharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Propanc Biopharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
